🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

57 results for “Central” Clear

  1. Apremilast, Apremilast, Apremilast

    Amgen

    Behçet’s disease is a chronic, relapsing, multisystem inflammatory disorder of unknown etiology characterized by 4 major symptoms (oral aphthous ulcers, genital ulcers, skin lesions, and ocular lesions) and occasionally by 5 minor symptoms (arthritis, gastrointestinal ulcers, epididymitis, vascular lesions, and central nervous system [CNS] symptoms) (Cho, 2012). Juvenile idiopathic arthritis is a heterogeneous group of chronic inflammatory disorders that initially presents in children by the age of 16 years. It refers to arthritis of at least 6 weeks duration of unknown etiology that begins in children less than 16 years old. Juvenile idiopathic arthritis has an annual incidence of 2 to 20 cases per 100 000 population and a prevalence of 16 to 150 cases per 100 000 population. It is an autoimmune disorder marked by abnormalities of immune responses (Adelowo, 2010).

    phase 3 small molecule active

    1 trial

  2. Busulfan (BU)

    The First People's Hospital of Lianyungang

    Primary Central Nervous System Lymphoma

    phase 3 small molecule active

    1 trial

  3. Donanemab, Florbetapir F18, Flortaucipir F18, Flortaucipir, FLORBETAPIR, SODIUM CHLORIDE PH. EUR.

    Eli Lilly Co.

    Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders

    phase 3 small molecule active

    1 trial

  4. LIPO-202

    Evofem Biosciences

    Central Abdominal Bulging

    phase 3 small molecule terminated

    2 trials

  5. PLACEBO, IMFINZI 50 mg/mL concentrate for solution for infusion., MYCOPHENOLATE MOFETIL, INFLIXIMAB, DOMVANALIMAB

    AstraZeneca AB

    The target population of interest in this study is participants with locally advanced (Stage III), unresectable NSCLC, whose tumours express PD L1 TC ≥ 1% as assessed by a central reference laboratory using the VENTANA PD-L1 (SP263) IHC assay, and who did not progress after definitive platinum based cCRT.

    phase 3 small molecule active

    1 trial

  6. Ranibizumab 0.5 mg

    Novartis Pharmaceuticals

    Central Retinal Vein Occlusion

    phase 3 small molecule completed

    1 trial

  7. TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, PLACEBO

    AstraZeneca AB

    Stage IB-IIIA non-small cell lung carcinoma, with a centrally confirmed, common sensitising EGFR mutations (Ex19del and L858R either alone or in combination with other EGFR mutations), following complete tumour resection with or without adjuvant chemotherapy

    phase 3 small molecule active

    1 trial

  8. TUCATINIB, CAPECITABINE, TUCATINIB, RO7771950, RO7771950, TRASTUZUMAB, CAPECITABINE, TRASTUZUMAB

    Hoffmann-La Roche

    Pretreated Unresectable Locally Advanced or Metastatic human epidermal growth factor receptor 2 (HER2)-Positive Breast Cancer, with or without Central Nervous System (CNS) Metastases

    phase 3 small molecule active

    1 trial

  9. Temomedac 20 mg hard capsules, Temomedac 5 mg hard capsules, Tirabrutinib, Temomedac 100 mg hard capsules, Truxima 500 mg concentrate for solution for infusion, Truxima 100 mg concentrate for solution for infusion

    Lacuna Pharma Pty Ltd

    Relapsed/refractory primary central nervous system lymphoma

    phase 3 small molecule active

    1 trial

  10. VEGF Trap-Eye 2.0mg

    Regeneron UK Limited

    Macular Edema Secondary to Central Retinal Vein Occlusion

    phase 3 mab completed

    1 trial

  11. centrally blinded product containing all the same manufactured ingredients and excipients as the DM199 formulation, except for the active pharmaceutical ingredient (API).

    DiaMedica Therapeutics

    Acute Ischemic Stroke

    phase 3 small molecule active

    1 trial

  12. filgrastim

    Hospital Authority, Hong Kong

    Brain and Central Nervous System Tumors

    phase 3 mab completed

    2 trials

  13. lomustine

    United Therapeutics Europe Ltd

    Brain and Central Nervous System Tumors

    phase 3 small molecule completed

    1 trial

  14. 601 1.25mg

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Central Retinal Vein Occlusion

    phase 2 small molecule completed

    1 trial

  15. Berubicin hydrochloride

    Rani Therapeutics Holdings

    central nervous system (CNS) lymphomas

    phase 2 small molecule active

    1 trial

  16. Carboplatin

    Children's Hospital of Fudan University

    Central Nervous System Nongerminomatous Germ Cell Tumor

    phase 2 small molecule completed

    1 trial

  17. EBVALLO

    Pierre Fabre Medicament

    EBV+ primary imunodeficiency lymphoproliferative disease (LPD), EBV+ post-transplant LPD where standard first line therapy (rituximab or chemotherapy) is inappropriate, including CD20-negative disease, EBV+ sarcomas, including leiomyosarcoma, or smooth muscle tumors, EBV+ associated post-transplant LPD involving the central nervous system (EBV+ CNS PTLD)

    phase 2 small molecule active

    1 trial

  18. GADOTERIC ACID, [18F]fludarabine

    Pari Pharma GmbH

    Patients with newly diagnosed primary central nervous system lymphoma naïve to surgery, radiotherapy or chemotherapy

    phase 2 small molecule active

    1 trial

  19. Hydroxycarbamid

    BRIGHT MINDS BIOSCIENCES INC.

    Central Retinal Vein Occlusion, Non-Ischemic

    phase 2 small molecule active

    1 trial

  20. Intravitreal Aflibercept Injection

    Regeneron UK Limited

    Central Retinal Vein Occlusion

    phase 2 small molecule completed

    1 trial

  21. Intravitreal Aflibercept Injection

    Regeneron UK Limited

    Central Serous Chorioretinopathy

    phase 2 small molecule completed

    1 trial

  22. Loc-R01: Randomized Phase IB/II Study of escalating doses of Lenalidomide and Ibrutinib in association with R-MPV as a targeted induction treatment for patients aged 18 to 60 (up to 65 for phase II) with a newly diagnosed Primary Central Nervous System Lymphoma

    The George Institute

    Primary Central Nervous System Lymphoma (PCNSL)

    phase 2 other active

    1 trial

  23. Methotrexate

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Primary Central Nervous System Lymphoma

    phase 2 small molecule active

    1 trial

  24. Mifepristone

    CORCEPT THERAPEUTICS INC

    Central Adrenal Insufficiency

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources